A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory Multiple Myeloma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515582-33-00

Acronym

MK-4002-001

Enrollment

Registered

2024-09-11

Start date

2020-10-26

Completion date

Unknown

Last updated

2025-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Multiple Myeloma that does not respond to treatment, Relapsed/Refractory Multiple Myeloma (RRMM)

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026